SG10201808312YA - Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines - Google Patents

Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines

Info

Publication number
SG10201808312YA
SG10201808312YA SG10201808312YA SG10201808312YA SG10201808312YA SG 10201808312Y A SG10201808312Y A SG 10201808312YA SG 10201808312Y A SG10201808312Y A SG 10201808312YA SG 10201808312Y A SG10201808312Y A SG 10201808312YA SG 10201808312Y A SG10201808312Y A SG 10201808312YA
Authority
SG
Singapore
Prior art keywords
aluminum salt
enhancing
methods
adsorbed
immunostimulation
Prior art date
Application number
SG10201808312YA
Inventor
Carl Alving
Jerome Kim
Mangala Rao
Original Assignee
The Government Of The Us Secretary Of The Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Government Of The Us Secretary Of The Army filed Critical The Government Of The Us Secretary Of The Army
Publication of SG10201808312YA publication Critical patent/SG10201808312YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16271—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

METHODS FOR ENHANCING THE IMMUNOSTIMULATION POTENCY OF ALUMINUM SALT-ADSORBED VACCINES Provided herein are (1) a method of mixing an aluminum salt-adsorbed immunogen with a monophosphoryl lipid A (MPLA)-containing liposome (L(MPLA)), and (2) the resulting immunogenic composition. The resulting immunogenic composition has an enhanced immunostimulation potency compared with either a composition comprising the uncapsulated immunogen mixed with the L(MPLA) or the aluminum salt-adsorbed immunogen alone. (FIG. 1)
SG10201808312YA 2014-03-25 2014-07-09 Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines SG10201808312YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461969905P 2014-03-25 2014-03-25

Publications (1)

Publication Number Publication Date
SG10201808312YA true SG10201808312YA (en) 2018-10-30

Family

ID=51302762

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201808312YA SG10201808312YA (en) 2014-03-25 2014-07-09 Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines
SG11201607404PA SG11201607404PA (en) 2014-03-25 2014-07-09 Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201607404PA SG11201607404PA (en) 2014-03-25 2014-07-09 Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines

Country Status (12)

Country Link
US (1) US20170165358A1 (en)
EP (1) EP3122379A1 (en)
JP (1) JP2017509713A (en)
KR (1) KR20170016315A (en)
CN (1) CN106535929A (en)
AU (1) AU2014388299A1 (en)
BR (1) BR112016021692A2 (en)
CA (1) CA2943050A1 (en)
MX (1) MX2016012166A (en)
RU (1) RU2016141621A (en)
SG (2) SG10201808312YA (en)
WO (1) WO2015147899A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108135167B (en) 2015-08-19 2021-07-09 哈佛学院院长及董事 Lipidated PSA compositions and methods
CA3030974A1 (en) * 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
JP7385206B2 (en) 2018-12-04 2023-11-22 国立大学法人大阪大学 immunostimulant
MX2023000904A (en) * 2020-07-22 2023-02-22 3H Bio Co Ltd Peptide for immunotherapeutic agent.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1124013A (en) * 1993-02-19 1996-06-05 史密丝克莱恩比彻姆公司 Influenza vaccine compositions containing 3-O-deacylated monophosphoryl lipid a
AU6141094A (en) * 1993-02-19 1994-09-14 Smithkline Beecham Biologicals (Sa) Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
DE69405551T3 (en) * 1993-03-23 2005-10-20 Smithkline Beecham Biologicals S.A. 3-0-DEAZYLATED MONOPHOSPHORYL LIPID A-CONTAINING VACCINE COMPOSITIONS
NZ560930A (en) * 2005-02-16 2011-06-30 Novartis Vaccines & Diagnostic Hepatitis B virus vaccine comprising a hepatitis B virus surface antigen, aluminium phosphate, 3-O-deacylated monophosphoryl lipid A and a triethylammonium ion
CA2687632C (en) * 2007-05-24 2013-01-15 Glaxosmithkline Biologicals S.A. Lyophilised antigen composition
AU2011231574A1 (en) * 2010-03-26 2012-10-11 Glaxosmithkline Biologicals S.A. HIV vaccine

Also Published As

Publication number Publication date
SG11201607404PA (en) 2016-10-28
BR112016021692A2 (en) 2017-08-15
RU2016141621A3 (en) 2018-05-11
JP2017509713A (en) 2017-04-06
CA2943050A1 (en) 2015-10-01
CN106535929A (en) 2017-03-22
US20170165358A1 (en) 2017-06-15
RU2016141621A (en) 2018-04-25
KR20170016315A (en) 2017-02-13
MX2016012166A (en) 2017-03-15
AU2014388299A1 (en) 2016-10-20
WO2015147899A1 (en) 2015-10-01
EP3122379A1 (en) 2017-02-01

Similar Documents

Publication Publication Date Title
EP3416679A4 (en) Pathogen vaccines and methods of producing and using the same
PH12018500947B1 (en) Crystal form, preparation method and intermediate of dihydropyrido ring compound
PH12017500762A1 (en) Proflavor delivery particles
EP3484508A4 (en) Compositions and methods for alphavirus vaccination
SG11202003800YA (en) Zika vaccines and immunogenic compositions, and methods of using the same
EP3413926A4 (en) Hiv vaccination and immunotherapy
EP3207142A4 (en) Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
EP3200831A4 (en) Vaccines having an antigen and interleukin-21 as an adjuvant
EP3463450A4 (en) Compositions and methods for tumor vaccination using prostate cancer-associated antigens
MY191539A (en) Streptococcal vaccine
EP3385286A4 (en) Vaccine antigen with increased immunogenicity
MX2016016746A (en) Dual adjuvant vaccine compositions, preparation and uses.
HK1255559A1 (en) Mg53 mutant, and preparation method therefor and uses thereof
EP3717511A4 (en) Zika vaccines and immunogenic compositions, and methods of using the same
MX2022013912A (en) Novel methods for inducing an immune response.
EP3308800A4 (en) Adjuvant for vaccines, vaccine, and immunity induction method
EP3118204A4 (en) O-phenyl chalcone compound and preparation method and use thereof
EP3454891A4 (en) Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration
EP3075393A4 (en) Adjuvant composition, vaccine composition comprising same, and method for producing same
SG10201808312YA (en) Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines
EP3241824A4 (en) Trifluoroacethydrazide compound as well as preparation method therefor and application thereof in preparing medicament
EP3730620A4 (en) Cross-immunizing antigen vaccine and method for preparation thereof
EP3543248A4 (en) PHOSPHORESCENT PtAg2 COMPLEX, PREPARATION METHOD THEREFOR AND USE THEREOF
EP3112351A4 (en) Naphthylamide compound, preparation method and use thereof
EP3630172A4 (en) Compositions and methods for tumor vaccination and immunotherapy involving her antigens